Issue 10-11/2004
Content (18 Articles)
Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia
A. Mouatt-Prigent, M.-P. Muriel, W.-J. Gu, K. H. El Hachimi, C. B. Lücking, A. Brice, E. C. Hirsch
Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress
C. Mytilineou, K. St. P. McNaught, P. Shashidharan, J. Yabut, R. J. Baptiste, A. Parnandi, C. W. Olanow
Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells
M. Shamoto-Nagai, W. Maruyama, Y. Akao, T. Osawa, F. Tribl, M. Gerlach, F. A. Zucca, L. Zecca, P. Riederer, M. Naoi
Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration
A. Storch, A. C. Ludolph, J. Schwarz
Cognitive and behavioral dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions
D. J. Zgaljardic, N. S. Foldi, J. C. Borod
Cognitive dysfunction and dementia in Parkinson’s disease
J. L. W. Bosboom, D. Stoffers, E. Ch. Wolters
Nicotinic receptors and cognition in Parkinson’s Disease: the importance of neuronal synchrony
P. B. Forgacs, I. Bodis-Wollner
Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson’s disease (MSPD)
C. E. Morrison, J. C. Borod, M. F. Brin, T. D. Hälbig, C. W. Olanow
Clinical advantages of COMT inhibition with entacapone – a review
A. Gordin, S. Kaakkola, H. Teräväinen
Dopamine receptor agonists in the therapy of Parkinson’s disease
P. Foley, M. Gerlach, K. L. Double, P. Riederer
Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease
D. Merims, H. Shabtai, A. D. Korczyn, C. Peretz, N. Weizman, N. Giladi
Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort
C. Peralta, P. Werner, B. Holl, S. Kiechl, J. Willeit, K. Seppi, G. Wenning, W. Poewe